The Current State of Targeted Agents in Rectal Cancer

Table 1

Pivotal randomized clinical trials of bevacizumab in mCRC.

Author	Phase	Study design (regimen)	𝑁 +Bev/−	Results	Comment	Reference
1st line
Hurwitz	III	IFL ± bevacizumab	402/411	20.3 versus 15.6 mo OS	RR,PFS,OS benefit	[9]
Scappaticci	II	5FU/LV ± bevacizumab	104/105	9.2 versus 5.5 mo PFS	No difference in OS, IFL was included in control group	[14]
Czito	III	IFL ± bevacizumab	249/251	17.9 versus 14.6 mo OS	RR,PFS,OS benefit	[15]
Saltz	III	CAPOX or FOLFOX ± bevacizumab	699/701	9.4 versus 8.0 mo PFS	No difference in OS	[16]
2nd line
Giantonio	III	FOLFOX ± bevacizumab	286/291	12.9 versus 10.8 mo OS	RR,PFS,OS benefit, No benefit in Bev alone group	[17]

RR: Response rate, PFS: Progression-free survival, OS: Overall survival.